Northwest Biotherapeutics Inc (NWBO) — 10-Q Filings
All 10-Q filings from Northwest Biotherapeutics Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
NWBO's Mounting Losses Raise Going Concern Doubts Amid Acquisition
— Nov 14, 2025 Risk: high
NORTHWEST BIOTHERAPEUTICS INC reported a net loss of $61.55 million for the nine months ended September 30, 2025, an increase from $55.55 million for the same p -
NWBO's Cash Up, But Going Concern Doubts Linger Amidst Losses
— Aug 14, 2025 Risk: high
NORTHWEST BIOTHERAPEUTICS INC reported a net loss of $34.7 million for the six months ended June 30, 2025, a slight improvement from the $36.2 million loss in t -
Northwest Biotherapeutics Files Q1 2025 10-Q
— May 15, 2025 Risk: medium
Northwest Biotherapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business -
Northwest Biotherapeutics Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
Northwest Biotherapeutics Inc. reported its Q3 2024 results on November 12, 2024. The company's financial statements for the period ending September 30, 2024, a -
Northwest Biotherapeutics Q2 2024: Assets $69.5M, Cash $550K
— Aug 9, 2024 Risk: high
Northwest Biotherapeutics Inc. reported its Q2 2024 results, with total assets of $69.5 million and cash and cash equivalents of $550,000 as of June 30, 2024. T -
Northwest Biotherapeutics Inc. Files 10-Q for Period Ending March 31, 2024
— May 10, 2024 Risk: medium
NORTHWEST BIOTHERAPEUTICS INC (NWBO) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Northwest Biotherapeutics Inc. filed a 10-Q report for the pe
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX